Fresenius Medical Care AG (FMS) EBITDA Margin (2009 - 2025)

Fresenius Medical Care AG (FMS) has reported EBITDA Margin for 17 consecutive years, with 18.7% the latest figure, recorded in Q4 2025.

• In Q4 2025, EBITDA Margin rose 138.0% year-over-year to 18.7%; the TTM figure through Dec 2025 stood at 16.67% (down 44.0% YoY), while the FY2025 annual figure was 19.04%, down 9.0% from the prior year.
• EBITDA Margin came in at 18.7% for Q4 2025 at Fresenius Medical Care AG, up from 9.75% in the prior quarter.
• The five-year high for EBITDA Margin was 99.56% in Q3 2021, with the low at 4.39% in Q4 2023.
• Average EBITDA Margin over 5 years is 47.11%, with a median of 18.05% recorded in 2024.
• Across the five-year window, EBITDA Margin sank 8057 bps in 2022 and surged 5364 bps in 2023, its largest moves.
• Year by year, EBITDA Margin stood at 86.35% in 2021, then slipped by 7 bps to 80.67% in 2022, then plunged by 95 bps to 4.39% in 2023, then soared by 295 bps to 17.32% in 2024, then grew by 8 bps to 18.7% in 2025.
• According to Business Quant data, EBITDA Margin over the past three periods registered 18.7%, 9.75%, and 16.72% for Q4 2025, Q3 2025, and Q2 2025 respectively.